Precision Medicine Study on Cardiovascular Disease (PRECISE)
PRECISE
1 other identifier
observational
20,000
1 country
1
Brief Summary
Cardiovascular diseases are the leading cause of death in China and have become a financial burden on society under the traditional medical model. A new and sustainable medical model is needed to solve this dilemma, for which precision medicine models have great potential. Monogenic cardiovascular disease is the first field to be broken through in precision medicine at this stage, and it is also the field where precision medicine is most likely to be successfully transformed into clinical application, including genetic diagnosis, molecular typing, risk stratification, genetic interruption and individualized treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2020
CompletedFirst Posted
Study publicly available on registry
June 17, 2020
CompletedStudy Start
First participant enrolled
March 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 10, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 10, 2030
ExpectedMarch 9, 2021
March 1, 2021
4.6 years
June 15, 2020
March 7, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
number of participants with cardiovascular deaths
including sudden cardiac death and deaths due to heart failure and stroke.
an average of 5 years
number of participants with all-cause death
deaths due to all cause.
an average of 5 years.
Secondary Outcomes (3)
number of participants with heart failure
an average of 5 years
number of participants with stroke
an average of 5 years
number of participants with malignant arrhythmia
an average of 5 years
Eligibility Criteria
Patients with monogenic cardiovascular disease from multiple centers in China between October 10, 2020 and October 10, 2025
You may qualify if:
- Patients with monogenic cardiovascular diagnosed according current practice guideline.
You may not qualify if:
- Patients who refuse to sign the informed consent or decline follow-up.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fuwai hospital
Beijing, Beijing Municipality, 100037, China
Biospecimen
Specimens retained include blood, saliva, urine, feces, and myocardium when the patients receive cardio myectomy surgery.
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Lei Song, MD. ph.D
Chinese Academy of Medical Sciences, Fuwai Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 15, 2020
First Posted
June 17, 2020
Study Start
March 10, 2021
Primary Completion
October 10, 2025
Study Completion (Estimated)
October 10, 2030
Last Updated
March 9, 2021
Record last verified: 2021-03